WideCells Group

Revenue generation commences with milestone binding agreement with White Apex

WideCells Group PLC (‘WideCells Group’ or ‘the Group’)   Revenue generation commences with milestone binding agreement with White Apex: stem cell services available for purchase in the Middle East, North Africa and Asia-Pacific territories

CellPlan expansion into Spain and e-commerce platform launched in UK

CellPlan is set to launch its first-of-its-kind stem cell healthcare insurance plan and medical concierge service in Spain.

Strategic Partner Secured to Expand into The Middle East, N.Africa and Asia

WideCells Group has signed an exclusive Heads of Terms agreement with multi-sector advisory business White Apex General Trading.

WideCells Group PLC Interim Results

29 September 2017 WideCells Group PLC ('WideCells Group' or 'the Company') Interim Results WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, announces its interim results for the 6 months ended 30 June 2017. Highlights Established revenue generative operations, with three primary divisions and five revenue streams Award winning - named 21st in Global DISRUPT 100 list, showing potential to influence, change and create new global markets, and nomination as ‘Life Science IPO of the year’ by Biotech&Money Successfully executed the landmark launch of the world’s first global stem cell insurance product, CellPlan, generating maiden revenues Secured a commercial agreement with the UK’s leading cord blood storage facility, Biovault, to capitalise on their 25,000 cord blood samples; Built e-commerce platform to facilitate rapid global rollout Post-period end signed a definitive agreement with Hemocord, a leading Brazilian storage facility, providing exposure to a new and rapidly growing market Strong growth pipeline – actively assessing a number of agreements with additional cord blood storage facilities   Commenced revenue generative research work and expanded product offering at WideCells Building a portfolio of global stem cell storage facilities to build upon current facility in Brazil and cryogenics facility in Manchester, UK Post-period end granted a Research Licence to proceed with the planned paid-for research work to drive development in stem cell therapies Post-period end identified strategic opportunity to target complementary growth opportunities within regenerative medicine by becoming a licenced provider of novel synthetic bone graft INDUS - maiden product sales targeted Q4 2017 selling to the UK dental industry in the coming months, with potential for further roll out internationally Advanced Wideacademy from vision to commercialisation, with revenue generation on track to commence in 2018 Former Director of Education at Apple, Alan Greenberg, appointed to drive development Finalised “route to market” through creation of an innovative Software as a Service ('Sas') platform to deliver authentic, factual and trustworthy content on stem cell treatments and life sciences Commercial launch targeted for Q1 2018 Cash position of £868,829 as at 30 June 2017 – post period end cash balances further bolstered through Placing to raise gross proceeds of £750,000 WideCells Group CEO Joao Andrade said, “I firmly believe WideCells Group is set to change our future medical landscape.  By creating the world's first end-to-end service solution, we are committed to making cord blood stem cell treatment accessible and affordable globally and I believe the repercussions of this are set to be huge.  “Having achieved consistent growth across our portfolio of three divisions during the period, we now have two revenue generative divisions – CellPlan and WideCells – with the third – Wideacademy – targeted to commence operations in early 2018.  With a number of growth initiatives already well advanced to build on revenues and expand our global reach, the future continues to look very bright for our company.  I would like to thank all of those who have made this rapid progress possible, and I look forward to updating our loyal shareholders in the future as we continue to expand and commercialise our products in this electric market.”  

Wideacademy image

Wideacademy developing game changing educational platform

September 2017 WideCells Group PLC (‘WideCells Group’ or ‘the Group’) Wideacademy: Development of a bespoke stem cell focused educational platform New Corporate Presentation and Attendance at Share Talk Investor Evening   WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, is pleased to announce that Wideacademy, its 100% owned education and training division, has designed an innovative Software as a Service (‘Sas’) platform (the ‘Platform’) to deliver authentic, factual and trustworthy content on stem cell treatments and life sciences.  The Platform is currently being developed, with commercial launch targeted for Q1 2018, and will aim to: Inform the medical industry of the benefits of stem cell treatment; Educate and inform consumers on stem cell innovation and best practice; and Partner with enterprise, within both the stem cell and insurance industry, to create training and digital resources.  

WideCells Group PLC

WideCells Group PLC raises £750,000 to expand & support the company's 3 division

15 August 2017 WideCells Group PLC (‘WideCells Group’ or ‘the Company’) Raises £750,000 to expand and support the Company’s three divisions WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, is pleased to announce that it has raised gross proceeds of £750,000 through the issue of 5,357,143 ordinary shares at 14p per share by way of a private placing (the ‘Placing’) with new and existing shareholders as well as the Board of Directors.  The funds raised will be used to execute on a range of additional opportunities the Group has identified since listing in July 2016, rapidly accelerate the roll out of its three stem cell services divisions, CellPlan, WideCells and WideAcademy, and further its penetration of the rapidly growing stem cell market.  

Research Licence Granted from the Human Tissue Authority (HTA)

WideCells Institute of Stem Cell Technology (ISCT), has been granted a Research Licence (the ‘Licence’) from the UK’s Human Tissue Authority (‘HTA’). 

New product offering to target the dental market

24 July 2017 WideCells Group PLC (‘WideCells Group’ or ‘the Group’) New product offering to target the dental market WideCells Group PLC, the healthcare services company focused on regenerative medicine, including the provision of stem cell services and ground-breaking insurance for stem cell treatment, is delighted to become a licenced provider of INDUS, a novel synthetic bone graft which promotes new bone formation.   The Group intends to start selling this new product in the UK in the coming months, initially targeting the dental industry, with potential for further roll out internationally. 

CellPlan launches E-Commerce Platform in the UK

WideCells Group PLC (‘WideCells Group’ or ‘the Group’) CellPlan launches E-Commerce Platform in the UK WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, is delighted to announce that the e-commerce platform of the Group’s 100% owned subsidiary, CellPlan Limited, will be made live today.  The platform facilitates the purchase of the Group’s stem cell insurance product CellPlan and will be launched initially in the UK, with potential to be rolled out to international countries and include additional product offerings over time.  The platform can be accessed using the following link: www.cellplan.com.

Definitive Agreement to Roll Out CellPlan to Leading Brazilian Storage Facility

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is pleased to announce that its 100% owned subsidiary CellPlan Limited (‘CellPlan’) has signed a Definitive Agreement (‘the Agreement’) which will see its first-of-its-kind stem cell healthcare insurance plan and medical concierge service offered to both new and existing clients of Hemocord Clinica Medica Ltd (‘Hemocord’). 

Private Investor Evening

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, is pleased to the confirm details of its upcoming Private Investor Event, to be held at 5.30pm on Wednesday 12 July 2017 at Shard Capital, 23rd floor, 20 Fenchurch St, London EC3M 3BY. 

CellPlan - Revenue with launch of first UK insurance product for stem cell treat

WideCells Group PLC (‘WideCells Group’ or ‘the Group’) CellPlan - Revenue with launch of first UK insurance product for stem cell treatment WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is delighted to announce that its 100% owned subsidiary, CellPlan Limited (‘CellPlan’), has launched a first-of-its-kind stem cell healthcare insurance in the UK with CellPlan now available for purchase by customers of Biovault Technical Ltd ('Biovault'), the UK's largest private human tissue storage facility. Additionally, the Company’s e-commerce platform, which allows the Group to sell CellPlan directly to families, will be made live during the next few weeks.  This marks an inflection point for the Group, with the generation of maiden revenues from CellPlan expected imminently.

AGM Statement and Notice of Investor Evening

WideCells Group PLC ('WideCells Group' or 'the Group') AGM Statement and Notice of Investor Evening WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, will hold its Annual General Meeting ('AGM') today.  After the AGM João Andrade, Chief Executive Officer, will provide a corporate update, highlighting the progress made since listing in all three divisions.  A new corporate presentation, which will be used by Mr Andrade to present with, can be found on the Company’s website later today: www.widecellsgroup.com.  Furthermore, the Company will be hosting a private Investor Evening on Wednesday 12 July 2017, further details of which are set out below. 

WideAcademy – Strategic Development Update

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is pleased to provide a strategic update on WideAcademy, its 100% owned education and training division. These strategic developments follow the recent Board appointment of Alan Greenberg, former Director of Education at Apple, as Non-Executive Director of WideCells Group and Senior Vice President of WideAcademy, and the recent Placing. 

WideCells Group PLC - Launch of CellPlan set to generate maiden revenues

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is pleased to provide an update on CellPlan, its revolutionary stem cell healthcare product, which is focused on making expensive stem cell treatment accessible and affordable to families around the world.

Disrupt 100

WideCells Group in the Top 100 Disrupt List

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is delighted to announce that it has been ranked as the 21st most disruptive company globally by DISRUPT 100.  

WideCells Dr. Marilyn Orcharton Attends BDA Conference 2017

WideCells Group (‘WideCells’ or ‘the Company’) Attendance at British Dental Conference and Exhibition WideCells Group PLC ('WideCells' or the 'Company'), the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is pleased to announce that Non-Executive Director Dr. Marilyn Orcharton will be representing the Company at the upcoming British Dental Conference and Exhibition, being held in Manchester from 25-27 May 2017.  At the conference, Dr. Orcharton will be providing information on the Company’s plans to extend its stem cell storage services to include dental pulp storage and processing (TeethCells).  The Company hopes to start offering this new service to the market in the coming months and, having recognised significant growth opportunities within the dental industry, intends to appoint a Dental Key Account Manager to manage this emerging revenue stream including potential strategic relationships with distribution partners in Europe and the Middle-East. Dr. Orcharton is a renowned figure in dentistry, having co-founded Denplan Limited in 1986, which is still the UK's market leader in dental insurance, with a multi-million-pound annual turnover.   WideCells is looking to achieve similar success in the stem cell industry via its CellPlan division, which is rolling out the world’s first stem cell healthcare insurance plan.    

Attendance at Brazilian Obstetrics and Gynaecology Conference

WideCells Group PLC ('WideCells' or the 'Company'), the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is pleased to announce its attendance at the Obstetrics and Gynaecology Conference in São Paulo, Brazil, 25-26 May 2017.  At the conference, Dr Niranjan Bhattacharya, a preeminent figure in the stem cell industry and founding member of CellPlan’s Stem Cell Panel, will be making a presentation on stem cell technology and the developments both he and WideCells are driving within the industry.   

Annual Report and Accounts 2016 & AGM

2 May 2017 WideCells Group PLC (‘WideCells Group’ or ‘the Company’)  Annual Report and Accounts for the year ended 31 December 2016 and Notice of Annual General Meeting WideCells Group PLC (‘WideCells’ or the ‘Company’), the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, announces that its Annual Report and Accounts for the year ended 31 December 2016 and a Notice of Annual General Meeting (“AGM”) have been posted to shareholders and are available to download on the Company’s website at http://www.widecellsgroup.com/. The AGM will be held on 22 June 2017 at the Core Technology Facility, 46 Grafton Street, Manchester, M13 9NT at 12.00 noon. **ENDS**

WideCells

Expansion placement completed

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is pleased to announce that it has raised gross proceeds of £648,696 by way of a private placing (the ‘Placing’). 

Preliminary results

WideCells Group PLC Unaudited Preliminary Results

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, announces its unaudited preliminary results for the period ended 31 December 2016. 

Former Director of Education at Apple Joins Board to Grow WideAcademy

WideCells Group, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is delighted to announce the appointment of former Director of Education at Apple, Mr. Alan Greenberg, to the Board as Non-Executive Director and Vice President (‘VP’) of WideAcademy, WideCells Group’s research and development (‘R&D’) and training division.

wideCel

WideCells Group PLC Director Purchases and Grant of Options

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is pleased to announce that Chairman  Dr.  Graham Hine, Chief Executive Officer João Andrade, Chief Financial Officer David Bridgland, Chief Operating Officer Lopes Gil and Non-Executive Director Marilyn Orcharton have purchased a combined total of 100,000 new ordinary shares in the Company (the 'Director Purchases').

WideCells Group PLC Grant of Options

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, announces that on 24 January 2017 the Company granted options ("Options") over 600,000 ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares") pursuant to the Company's EMI Share Option Plan, and 270,290 ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares") pursuant to the Company's 2017 Share Option Plan For Consultants And Non-Executive Directors.  These Options were granted to Persons Discharging Managerial Responsibilities ("PDMRs") on behalf of the Company.

CellPlan Logo

WideCells Group PLC Secures two LOIs for CellPlan

WideCells Group PLC, the healthcare services company focused on providing stem cell services and  ground breaking  insurance for stem cell treatment, is pleased to provide an update on the continued commercialisation of its 100% owned subsidiary CellPlan Limited (‘CellPlan’), which has developed the world's first stem cell  healthcare  insurance plan and medical concierge service.  Having recently secured a maiden definitive agreement with Biovault Technical Ltd, the UK's largest private human tissue storage facility (‘Biovault’), to roll-out CellPlan to Biovault’s significant customer base (see announcement dated 9 January 2017), the Company is delighted to have signed two further non-binding Letter of Intent ('LOI') agreements to support the continued roll-out of CellPlan globally.  The Company has also developed a new commercial CellPlan product, YOUR EXPERT CONSULTATION, further bolstering CellPlan’s innovative service offering and creating a new revenue opportunity.

Definitive Agreement to Roll Out CellPlan to Customers of Cord Blood Store

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is pleased to announce that, further to its announcement released on 7 November 2016, its 100% owned subsidiary CellPlan Limited (‘CellPlan’), which has developed the world's first stem cell healthcare insurance plan and medical concierge service, has cemented its agreement with Biovault Technical Ltd (‘Biovault’) via a definitive agreement, which covers an initial five-year term.

WideCells Group PLC webs

WideCells Group signs LOI with medical device company

WideCells Group PLC signs LOI with medical device company to undertake stem cell research at WideCells’ Manchester Institute of Stem Cell Technology

WideCells Group PLC Signs LOI with First Cord Blood Bank

CellPlan Limited (‘CellPlan’), which has developed the world's first stem cell healthcare insurance plan and medical concierge service, has signed a non-binding Letter of Intent (‘LOI’) with Biovault Technical Ltd. 

Corporate Update - 24.10.2016

Recognising the instrumental role a highly skilled team will play in delivering on its strategic vision, the Group has made additional key personnel appointments across its three core divisions

Update on CellPlan - An innovative Stem Cell Insurance Plan

WideCells Group PLC, the healthcare services company focused on providing stem cell banking services and ground breaking insurance for stem cell treatment, is pleased to announce that it has finalised the terms and conditions for CellPlan, the world’s first stem cell healthcare insurance plan and medical concierge service, which was launched to cord blood banks in May 2016 at the World Cord Blood Congress in London.  

WideCells Group PLC Partner With University of Westminster

WideCells Group PLC  is pleased to announce that its R&D and training development division, WideAcademy, has finalised its syllabus of short courses focused on educating healthcare professionals on the benefits of stem cell storage and treatment.

Update on Manchester Facility and Appointments

WideCells Group, the healthcare services company focused on collecting and storing stem cells and providing ground breaking insurance for stem cell treatment, is pleased to announce...

P

WideCells Group PLC Publication of Prospectus

WideCells Group PLC Publication of Prospectus